A. Stahler

发表

Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5‐FU/LV plus irinotecan or irinotecan plus oxaliplatin as first‐line treatment (FIRE 1‐trial)

M. Stauch, A. Crispin, V. Heinemann, 2016, International journal of cancer.

Current treatment options in RAS mutant metastatic colorectal cancer patients: a meta-analysis of 14 randomized phase III trials

V. Heinemann, C. Westphalen, S. Stintzing, 2020, Journal of Cancer Research and Clinical Oncology.

Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer

M. Stauch, A. Crispin, V. Heinemann, 2017, Anti-cancer drugs.

FIRE-9 – PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer

L. Bullinger, G. Rauch, V. Heinemann, 2022, BMC Cancer.

Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study).

V. Heinemann, T. Decker, C. Denzlinger, 2020, European journal of cancer.

Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE‐3)

V. Heinemann, J. Holch, T. Decker, 2021, International journal of cancer.

FIRE-7-Studie (AIO-KRK-0120)

V. Heinemann, J. Holch, J. Pratschke, 2021, Forum.

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

V. Heinemann, W. Schmiegel, H. Schmoll, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials

M. Stauch, V. Heinemann, T. Decker, 2020, Clinical Cancer Research.

Impact of exact segment by segment primary tumor location status on anti-EGFR antibody first-line treatment efficacy in RAS/BRAF wild-type and BRAF mutant metastatic colorectal cancer. A pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI.

V. Heinemann, T. Decker, A. Tannapfel, 2021 .

Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306

U. Neumann, V. Heinemann, D. Seehofer, 2020, Annals of Surgical Oncology.

Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy

V. Heinemann, T. Decker, A. Tannapfel, 2022, Cancers.

Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110).

V. Heinemann, T. Decker, G. Schuch, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110).

V. Heinemann, T. Decker, C. Denzlinger, 2022, European journal of cancer.

Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal

V. Heinemann, C. Roderburg, A. Kiani, 2022, BMC cancer.

Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3

W. Scheithauer, M. Stauch, V. Heinemann, 2022, British Journal of Cancer.

Serial Analysis of Gene Mutations and Gene Expression during First-Line Chemotherapy against Metastatic Colorectal Cancer: Identification of Potentially Actionable Targets within the Multicenter Prospective Biomarker Study REVEAL

F. Klauschen, V. Heinemann, J. Holch, 2022, Cancers.

Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).

V. Heinemann, T. Trarbach, S. Kasper, 2022, European journal of cancer.

Should routine risk reduction procedures for the prevention and control of pandemics become a standard in all oncological outpatient clinics? The prospective COVID-19 cohort study: protect-CoV

H. Blum, E. Khatamzas, S. Krebs, 2022, Medical Oncology.

Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance

M. Gerlinger, F. Klauschen, V. Heinemann, 2022, Journal of Cancer Research and Clinical Oncology.

Patients with colorectal cancer and brain metastasis: The relevance of extracranial metastatic patterns predicting time intervals to first occurrence of intracranial metastasis and survival

J. Kleeff, V. Heinemann, J. Holch, 2020, International journal of cancer.

Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial.

W. Scheithauer, V. Heinemann, T. Decker, 2020, European journal of cancer.

Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial).

V. Heinemann, T. Decker, C. Denzlinger, 2021, European journal of cancer.

NeoRAS wild-type in metastatic colorectal cancer: Myth or truth?-Case series and review of the literature.

U. Keilholz, S. Stintzing, H. Osumi, 2021, European journal of cancer.

Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212)

V. Heinemann, T. Trarbach, S. Kasper, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Herpes Zoster als Risikofaktor für Malignome Herpes Zoster as a Risk Factor for Malignancy

J. Schelling, L. Sanftenberg, A. Stahler, 2016 .

Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110).

V. Heinemann, T. Decker, C. Denzlinger, 2021, European journal of cancer.

Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy—Analysis of the Phase 3 XELAVIRI Trial

V. Heinemann, T. Decker, C. Denzlinger, 2022, Frontiers in Oncology.

Corrigendum to 'Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial'. [European Journal of Cancer 137 (2020) 250-259].

W. Scheithauer, V. Heinemann, T. Decker, 2022, European journal of cancer.

Clonal hematopoiesis associates with improved survival in metastatic colorectal cancer patients from the FIRE-3 trial.

L. Bullinger, S. Ogawa, V. Heinemann, 2021, Blood.

Importance of interdisciplinarity in modern oncology: results of a national intergroup survey of the Young Oncologists United (YOU)

C. Kropf-Sanchen, L. Lazaridis, T. Huber, 2023, Journal of Cancer Research and Clinical Oncology.

Association of microRNA-21 with efficacy of cetuximab in RAS wild-type patients in the FIRE-3 study (AIO KRK-0306) and microRNA-21’s influence on gene expression in the EGFR signaling pathway.

W. Scheithauer, V. Heinemann, S. Al-Batran, 2019, Journal of Clinical Oncology.

Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212)

V. Heinemann, T. Trarbach, K. Caca, 2023, ESMO open.

Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials.

T. Trarbach, H. Wasan, E. Díaz-Rubio, 2023, European journal of cancer.

Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)

V. Heinemann, T. Trarbach, S. Kasper, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

V. Heinemann, T. Trarbach, S. Kasper, 2023, European journal of cancer.

Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIO KRK0110 (ML22011)- study.

V. Heinemann, T. Decker, G. Schuch, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer

M. Menden, J. Holch, Alexander J Ohnmacht, 2023, Nature communications.

Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110).

V. Heinemann, T. Decker, G. Schuch, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the PanaMa trial (AIO KRK 0212)

T. Trarbach, S. Haas, E. Goekkurt, 2023, International journal of cancer.

FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases: The PARLIM trial (AIO KRK 0314).

V. Heinemann, S. Kasper, C. Junghanss, 2021, Journal of Clinical Oncology.

Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI.

A. Stahler, A. Alig, K. Heinrich, 2024, ESMO open.

Molecular testing and liquid biopsies in colorectal cancer

A. Stahler, S. Stintzing, 2024, Die Gastroenterologie.